Literature DB >> 17499229

Overexpression of histidine-rich Ca-binding protein protects against ischemia/reperfusion-induced cardiac injury.

Xiaoyang Zhou1, Guo-Chang Fan, Xiaoping Ren, Jason R Waggoner, Kimberly N Gregory, Guoli Chen, W Keith Jones, Evangelia G Kranias.   

Abstract

OBJECTIVE: The histidine-rich Ca-binding protein (HRC) is a Ca-storage protein in cardiac sarcoplasmic reticulum. Recent transgenic studies revealed that this protein inhibits the maximal rates of sarcoplasmic reticulum Ca-transport, leading to cardiac dysfunction. In view of the role of sarcoplasmic reticulum Ca-cycling in myocardial ischemia/reperfusion injury, we designed this study to gain further insight into the role of HRC during ischemia/reperfusion. METHODS AND
RESULTS: The transgenic mouse model with cardiac-specific overexpression of HRC was utilized and cardiac contractile parameters were assessed before and after ischemia/reperfusion injury by Langendorff perfusion. After a 20-min stabilization period, the hearts were subjected to 40 min of global ischemia, followed by 60 min of reperfusion. We found that although transgenic (TG) hearts showed depressed cardiac function (25%) compared to wild types (WTs) at baseline, they exhibited better recovery of left ventricular developed pressure (86.6+/-2.6% in TGs vs. 58.3+/-4.0% in WTs of pre-ischemic values, P<0.05) and higher rates of contraction and relaxation after ischemia/reperfusion than WTs. This improvement was accompanied by smaller infarcts (23.1+/-1.7% in TGs vs. 41.1+/-2.5% in WTs of infarct region-to-risk region ratio, P<0.05) and lower creatine kinase release. Notably, the extent of apoptotic cell death was significantly attenuated, as evidenced by decreased DNA fragmentation, upregulation of the antiapoptotic protein Bcl-2, and downregulation of the active caspases (3, 9 and 12) following ischemia/reperfusion in TG hearts, compared with WTs. Extension of these studies to an in vivo model of 30-min myocardial ischemia, via coronary artery occlusion, followed by 24-h reperfusion, showed that the infarct region-to-risk region ratio was 9+/-0.9% in TGs, compared with 20.4+/-2.9% in WTs (P<0.05).
CONCLUSIONS: Our findings suggest that increased cardiac HRC expression protects against ischemia/reperfusion injury in the heart, resulting in improved recovery of function and reduced infarction.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17499229     DOI: 10.1016/j.cardiores.2007.04.005

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  10 in total

1.  Molecular and functional analyses of aspolin, a fish-specific protein extremely rich in aspartic acid.

Authors:  Shigeharu Kinoshita; Eriko Katsumi; Hiroshi Yamamoto; Kazuharu Takeuchi; Shugo Watabe
Journal:  Mar Biotechnol (NY)       Date:  2010-09-29       Impact factor: 3.619

Review 2.  Organellar calcium buffers.

Authors:  Daniel Prins; Marek Michalak
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-03-01       Impact factor: 10.005

3.  Ablation of junctin or triadin is associated with increased cardiac injury following ischaemia/reperfusion.

Authors:  Wen-Feng Cai; Tracy Pritchard; Stela Florea; Chi-Kueng Lam; Peidong Han; Xiaoyang Zhou; Qunying Yuan; Stephan E Lehnart; Paul D Allen; Evangelia G Kranias
Journal:  Cardiovasc Res       Date:  2012-03-12       Impact factor: 10.787

Review 4.  Histidine-rich calcium binding protein: the new regulator of sarcoplasmic reticulum calcium cycling.

Authors:  Demetrios A Arvanitis; Elizabeth Vafiadaki; Despina Sanoudou; Evangelia G Kranias
Journal:  J Mol Cell Cardiol       Date:  2010-08-31       Impact factor: 5.000

5.  Inducible expression of active protein phosphatase-1 inhibitor-1 enhances basal cardiac function and protects against ischemia/reperfusion injury.

Authors:  Persoulla Nicolaou; Patricia Rodriguez; Xiaoping Ren; Xiaoyang Zhou; Jiang Qian; Sakthivel Sadayappan; Bryan Mitton; Anand Pathak; Jeffrey Robbins; Roger J Hajjar; Keith Jones; Evangelia G Kranias
Journal:  Circ Res       Date:  2009-03-19       Impact factor: 17.367

Review 6.  Junctin and the histidine-rich Ca2+ binding protein: potential roles in heart failure and arrhythmogenesis.

Authors:  Tracy J Pritchard; Evangelia G Kranias
Journal:  J Physiol       Date:  2009-04-29       Impact factor: 5.182

7.  Targeted ablation of the histidine-rich Ca(2+)-binding protein (HRC) gene is associated with abnormal SR Ca(2+)-cycling and severe pathology under pressure-overload stress.

Authors:  Chang Sik Park; Shan Chen; Hoyong Lee; Hyeseon Cha; Jae Gyun Oh; Sunghee Hong; Peidong Han; Kenneth S Ginsburg; Sora Jin; Inju Park; Vivek P Singh; Hong-Sheng Wang; Clara Franzini-Armstrong; Woo Jin Park; Donald M Bers; Evangelia G Kranias; Chunghee Cho; Do Han Kim
Journal:  Basic Res Cardiol       Date:  2013-04-04       Impact factor: 17.165

8.  Ablation of phospholamban rescues reperfusion arrhythmias but exacerbates myocardium infarction in hearts with Ca2+/calmodulin kinase II constitutive phosphorylation of ryanodine receptors.

Authors:  Carlos A Valverde; Gabriela Mazzocchi; Mariano N Di Carlo; Alejandro Ciocci Pardo; Nehuen Salas; María Ines Ragone; Juan I Felice; Alejandra Cely-Ortiz; Alicia E Consolini; Enrique Portiansky; Susana Mosca; Evangelia G Kranias; Xander H T Wehrens; Alicia Mattiazzi
Journal:  Cardiovasc Res       Date:  2019-03-01       Impact factor: 10.787

9.  The Protective Effects of Hydrogen Sulfide New Donor Methyl S-(4-Fluorobenzyl)-N-(3,4,5-Trimethoxybenzoyl)-l-Cysteinate on the Ischemic Stroke.

Authors:  Jing Fan; Junxi Du; Zhongwei Zhang; Wenjing Shi; Binyan Hu; Jiaqin Hu; Yan Xue; Haipeng Li; Wenjin Ji; Jian Zhuang; Pengcheng Lv; Kui Cheng; Kun Chen
Journal:  Molecules       Date:  2022-02-25       Impact factor: 4.411

10.  AAV-mediated knock-down of HRC exacerbates transverse aorta constriction-induced heart failure.

Authors:  Chang Sik Park; Hyeseon Cha; Eun Jeong Kwon; Dongtak Jeong; Roger J Hajjar; Evangelia G Kranias; Chunghee Cho; Woo Jin Park; Do Han Kim
Journal:  PLoS One       Date:  2012-08-28       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.